Randox Biosciences: dedicated to advancing scientific discovery

Home - Research

Randox Biosciences: dedicated to advancing scientific discovery

Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.

From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.

Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.

We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.

 

If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at info@randoxbiosciences.com.

 

 

 

 

 

 

 

 


Study by Center for Disease Dynamics finds dramatic rise in global antibiotic consumption

A dramatic increase in global consumption of antibiotics has led public health experts to call for innovative new ways to rein in excessive use of the drugs, following a study by the Centre for Disease Dynamics, Economics and Policy, in Washington DC.

The study found a 65% rise in worldwide consumption of antibiotics from 2000 to 2015, despite efforts to encourage more prudent use of the drugs. The unrestrained use of antibiotics is the main cause of the increasing appearance of drug-resistant infections, which now kill more than half a million people worldwide. A report in 2014 predicted that the spread of drug resistance could claim millions of lives per year by 2050.

Eili Klein, an author of the study, which was published in Proceedings of the National Academy of Science, criticised the global response to the global antibiotic resistance crisis as “slow and inadequate” and called for a “radical thinking” of antibiotic consumption.

At Randox, our pioneering R&D teams have developed a revolutionary swab test for respiratory infections which will help to reduce the unnecessary prescription of antibiotics. Earlier this year, Public Health England reported that 59% of people who visited their GP with a sore throat were prescribed antibiotics, in spite of only 13% actually needing them.

The new Randox swab test indicates the cause of the infection and whether a patient needs antibiotics or not, by rapidly detecting and identifying the cause of 21 respiratory infections in just 5 hours

The test assists the clinician in prescribing the appropriate antibiotic.

John Lamont, Lead Scientist at Randox Laboratories, said;

“Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral in the way our new respiratory test can.”

This test, if widely adopted, could allow medical practitioners to make the correct treatment choice on the same day as examination and before patients have already begun a precautionary course of inefficient antibiotics. It would also have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily prescribing drugs which are not needed.

This new rapid and accurate test will give clinicians confidence in their diagnosis of respiratory infections and will allow for quicker treatment if necessary, which benefits patient outcomes. By reducing the prescription of unnecessary antibiotics, we can limit their use only for when they are truly needed.

The test is also available as a Randox Health Cough, Cold & Flu offering, and can be carried out by booking an appointment with Randox Health at our clinics in Crumlin, Holywood or London, or by arranging the mobile clinic to visit you at your home or place of work.

Book an appointment with one of our clinics, or arrange the mobile clinic, by phoning 0800 2545 130 or by clicking here.

For further information about the Randox Respiratory Infection Array please contact the Randox PR team by email: randoxpr@randox.com or phone 028 9442 2413

 

 

 


Randox Biosciences: dedicated to advancing scientific discovery

Randox Laboratories is an international clinical diagnostic solutions company with over 35 years’ experience in the industry. Randox is a global market leader, providing revolutionary products for laboratories worldwide and is dedicated to improving health.

Randox Biosciences is part of Randox Laboratories and is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions; Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use.

From initial cultivation of raw materials for assay development, through to providing companion diagnostics, custom and molecular based assays across a range of therapy areas; Randox Biosciences is a trusted partner supplying quality diagnostic solutions to the clinical, life science, pharmaceutical, research and biopharma industries. We specialise in supplying academic centres, genetics laboratories and the global biopharmaceutical industry with products tailored to their specific needs.

Randox Biosciences Research team encompasses a knowledgeable group of who are dedicated to assisting your research project to completion. Recently, the research team has expanded to include Business Development Executives in America to support academic centres of excellence achieve their potential while utilising our quality products. We are proud to welcome Rebecca Newburg who will be focusing her efforts on the US-Midwest market and Celestine Eshiet who will be working on the US -West Coast.

We cover five areas of research such as Sport and Exercise, Cardiovascular, Metabolic, Immunology and Oncology. These five areas include our Metabolic Syndrome Array 1 & 2, Cytokine Arrays and Cardiac Array including CK-MB, H-FABP, Myoglobin and Troponin.

 

If you work in an academic centre and are interested in our variety of arrays, analysers whether that be chemistry or immunoassay analysers, or our reagents or quality control please do not hesitate to contact us at info@randoxbiosciences.com.

 

 

 

 

 

 

 

 


£50m Randox Centres of Excellence launched in Northern Ireland

A record £50 million investment which will deliver cutting-edge technologies to diagnose conditions like cancer, heart conditions and infectious diseases has been announced by Northern Ireland diagnostics company Randox Laboratories and Invest Northern Ireland.

This major project involves the establishment of three Centres of Excellence, enabling Randox R&D scientists to work collaboratively with colleagues from Queen’s University Belfast and Ulster University. The centres are being officially launched today at the Randox Science Park. The ceremony will include a keynote address from Sir John Bell, who chaired the UK Government’s Life Sciences Industrial Strategy Board.

Advanced diagnostics have been identified as key to delivering sustainable improvement to healthcare systems struggling to cope with increasing levels of chronic and preventable conditions. Having been focused in this field for over 36 years, Randox has a successful track record of developing new and innovative tests – examples include assessing those at risk of Alzheimer’s disease and genetic cardiac conditions, to promote and enable preventive treatment, and a new clinically-approved test to diagnose prediabetes.

Managing Director of Randox Laboratories, Dr Peter FitzGerald, who today launched the three Centres of Excellence, said;

 “When almost a quarter of the deaths of people under 75 in the UK are considered preventable, we need to ask ourselves what can be done to improve healthcare outcomes. There is an undeniable case for radical change in the way healthcare is delivered, and sophisticated diagnostics will be at the fore of this revolution.

“Enabling earlier and more accurate diagnosis, to identify those at the earliest stages of illness, ideally before the onset of any symptoms, is a game-changer. Through early intervention we can restrict the development of chronic conditions and improve people’s lives. Our view of the future is one where people are empowered through earlier diagnosis to stay healthier for longer, and where healthcare systems are freed to deliver quality services to patients. Our announcement today demonstrates our continuing commitment in this field.

“We are grateful for the support offered by Invest NI and look forward to addressing these pressing healthcare needs.”

The Centres of Excellence will focus respectively on clinical diagnostics, engineering for biosciences and quality control. The project, which will strengthen collaborative partnerships between Randox, Queen’s University Belfast and Ulster University, will accelerate the development of new technologies and drive healthcare improvements regionally, nationally and across the globe.

Of the £23m of support offered by Invest NI, £5m will go toward research projects at Ulster University and Queen’s University Belfast.

Welcoming the investment, Alastair Hamilton, Chief Executive of Invest NI said;

“Randox has a long history of investing heavily in innovation and R&D which has enabled it to create a globally competitive export driven business, capable of developing world leading research. This major investment will enable Randox to perform cutting-edge R&D which has the potential to revolutionise the global healthcare industry. This is excellent news for Northern Ireland’s life and health sciences sector. Northern Ireland is enjoying a growing international reputation as a region of expertise and knowledge in key areas such as Diagnostics, Precision Medicine and Advanced Manufacturing. The three new Centres of Excellence will help build on this and enhance Northern Ireland’s credibility, provide supply chain opportunities, and encourage knowledge transfer with our universities.”    

Sir John Bell, commenting on the potential for the UK Life Sciences sector said;

“The life sciences industry represents one of the dominant economic sectors in the UK, and one with considerable potential for growth.   However, whilst we have many natural strengths we cannot afford to be complacent.  We must strive to optimise our science base, to encourage collaboration across academia, industry and the NHS, and grow our industrial capabilities.  To do so we need to use our extensive data sets to best effect, and have in place a strong skills strategy.  Success requires vision and drive.  To that end I would like to congratulate Dr FitzGerald and Randox in the establishment of these three R&D collaborative Centres of Excellence – these are assets of national standing and will have a meaningful impact in enabling earlier and more accurate diagnosis, driving improvements in patient care, regionally, nationally and globally.  They are leaders in this field, committed to innovation, and I wish them every success.”

Professor Jim McLaughlin, Director of Ulster University’s Nanotechnology and Integrated Bioengineering Centre, added;

“This very welcome investment enables pioneering Randox-inspired engineering capacity at Ulster University and reflects our research commitment to the life sciences industry. From nanotechnology to the development of systems that will enable large scale laboratory capability to be produced in the palm of your hand, the partnership brings shared industry and academic research excellence from the lab into the marketplace. Life sciences is a vital economic sector locally and this collaboration will advance diagnostics and ultimately enhance patient health outcomes.”

Dr David Jess, Senior Lecturer at Queen’s University Belfast School of Mathematics and Physics, added;

“The Randox Centres of Excellence will allow Queen’s University Belfast to continue to deliver cutting-edge and world leading research. We look forward to collaborating further with industry to develop pioneering research, focused on the needs of society.”

Invest NI’s R&D support is part funded by ERDF under the EU Investment for Growth and Jobs Programme 2014 – 2020.

For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com 

 


We Are Randox | Meet the team in Bangalore, India

Here at Randox, we’re a diverse bunch, spread over 145 countries in the world. We have more than 1400 employees of 44 nationalities, including 300 research scientists and engineers. Needless to say, the Randox family is a multicultural one!

We have four key manufacturing and R&D sites – in County Antrim, Northern Ireland; Dungloe, County Donegal, Ireland; Bangalore, India; and the Greater Washington DC area, in the U.S. This month, our We Are Randox article focuses on the team in Bangalore.

Randox India, located alongside other high-tech industries based in Bangalore, consists of 37 office staff and 77 field staff, including customer support engineers and sales managers. A base for administration, sales and manufacturing in India, the Bangalore site, set in the capital of the Indian state of Karnataka, services the 3.3 million square kilometre country.

Photographed are members of the Randox team in Bangalore from the following departments;

  • Accounts and Finance
  • Customer Support Engineers
  • Logistics and Trading
  • Manufacturing
  • Quality Control
  • Research & Development
  • Administration
  • Travel
  • Human Resources

Brian Walsh, Manufacturing Manager at Randox India, said:

“The photograph below was taken during this year’s Diwali, which is the Hindu festival of lights celebrated every year in autumn in the northern hemisphere. Danny Maguire, who is based in Ardmore at Randox HQ, was over on business at the time and joined us in celebrating this cultural tradition.

“It is one of the most popular festivals of Hinduism, and spiritually signifies the victory of light over darkness, good over evil, knowledge over ignorance, and hope over despair.

“We all really enjoyed having Danny with us and sharing some of our customs and values with him, many of which our team members based in other sites across Randox would not know about.

“We hope to welcome many more of our colleagues from across the globe to Randox India in the near future!”

Want to know what it’s like to work in Bangalore? Read all about when we met up with Pankaj Chitkara, who is our National Sales Manager for the RX Series in India.

For further information on the Randox Bangalore team, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413


RCLS – at the cutting edge of laboratory innovation

Randox Clinical laboratory Services (RCLS) is the latest offering from Randox, Built over 35 years of experience producing high quality IVD products, Randox Clinical Laboratory Services (RCLS), is dedicated to providing a clinical laboratory service designed to meet the time sensitive, bespoke requirements of research and clinical projects globally.

RCLS currently has four state of the art, fully functional ISO12025 accredited laboratories across the UK. They are situated in Liverpool, London and two in Northern Ireland, Hollywood and Randox Science Park in Antrim. RCLS looks to expand their team of experienced scientists, working towards further accreditations and furthermore setting up two additional labs in Dubai and Los Angeles. The addition of these purpose built labs will give RCLS the ability to increase output to both the health and research market.

Ann-Marie Jennings, Laboratory Manager for Randox Clinical Laboratory Services, discusses the Randox Biochip Array, RCLS’ abilities and confidence in testing;

“On our patented Randox Biochip Array Technology we can customize bespoke testing platforms based on the requirements of each drug development project, which can be a challenging process. From initial product development to clinical trial stages there can be a number of barriers and time constraints before drugs are successfully released to the public.  We’re confident that our newly enhanced capabilities will benefit patients suffering from conditions in most need of research by offering pharmaceutical companies at the forefront of pioneering research, with the latest technological developments.”

Thanks to these state of art laboratories, RCLS will now be able to provide an increasingly wide range of testing services to Biotechnology, research and pharmaceutical companies delivering the testing services required to support their research and drug development projects.

With the ability to conduct an unrivalled range of health testing – haematology, biochemistry and immunoassay – all under one roof, the laboratory offers unparalleled support services to the dynamic and growing healthcare industry.  With a greater understanding of human complexity, pharmaceutical companies are now focusing on developing safer drugs tailored to specific patient groups or sub-groups and the expansion plans in motion at RCLS will help these organisations bring new drugs to market faster.

If you would like more information on Randox Clinical Laboratory Services, please contact us by emailing us at info@rcls.com

 


What is RCLS? Randox Clinical Laboratory Services Explained

Randox Laboratories has over 35 years’ experience producing high quality IVD products. Randox Clinical Laboratory Services (RCLS), has built upon this experience and is Randox’s latest offering, dedicated to providing a clinical laboratory service designed to meet the time sensitive, bespoke requirements of clinical and research projects globally.

Facilities and Analysers

RCLS is a state of the art ISO 17025 accredited central laboratory with unrivalled facilities. A knowledgeable and proficient team is situated at each of the three locations.

There are a variety of analyser platforms available across the RCLS laboratories including the RX series of clinical chemistry analysers along with our Evidence Series of multiplex immunoassay/molecular diagnostic systems which utilise our intelligent Biochip Array Technology.  Each site also offers alternative third party analysers.

The Process

RCLS has the capability to collect your samples for testing via our third party courier service. The samples will then arrive at your chosen facility where they will be labelled with a unique identifier and uploaded onto our 21 CFR Part II compliant LIMS system. Full sample traceability is guaranteed through our integrated LIMS system. Short and medium term sample storage at -20 and -80 is also available.

Once each sample has been tested you will receive your results. We are flexible with the data transfer options available, which include couriered CD/USB, a secure email or alternatively uploaded to a sponsor database or server. Your sample results can be sent via a method which is convenient for you.

Capabilities

The capabilities of Randox Clinical Laboratory Services incorporate over 220 clinical and safety tests, 300 biomarkers and 80 Biochip Array Technology multiplex panels built in-house. We offer molecular arrays across a variety of disease such as our Sexually Transmitted Infection array. We also offer comprehensive ELISA project capabilities, selecting and validating the most appropriate reagent to match individual requirements. If you require your samples to be tested as part of a clinical trial or a research project we are on hand to help accelerate your project.

If you would like more information on Randox Clinical Laboratory Services, please contact us by emailing us at info@rcls.com


We Are Randox | Parkinson’s disease documentary leads to Film Festival Award for R&D Scientist Carol Naughton

Behind the doors of Randox, ground breaking scientific research is happening.

From Alzheimer’s disease to gastro-intestinal disorders, bladder cancer to cardiovascular disease, diabetes to kidney injury, our team of R&D scientists work on pioneering research projects in the areas of health that matter most, and ultimately, they save lives.

This week, we spoke to Carol Naughton, R&D Scientist in our Randox Teoranta team in Donegal, who has recently been part of an award-winning film documentary which aims to let people into the minds, the labs and the projects of scientists working on pioneering health research like that which takes place in Randox.

The film project, called ‘Feats of Modest Valour’, focuses on the lives of three individuals with Parkinson’s disease, Brian, Tom and Milena, and on a team of scientists working to find a cure for the condition. Aiming to bridge the gap between scientists and the very people the research will have the most impact on, Carol explains how working with Parkinson’s disease sufferers was the most humbling experience of her life.

Here’s Carol’s story.

 

The opportunity to be involved with Feats of Modest Valour (FOMV) was a gradual one. It was towards the end of my PhD when my supervisor, Dr. Eilis Dowd was awarded a grant as part of an EU consortium called Horizon 2020, with a new initiative to cure Parkinson’s disease. One of the remits of being in receipt of this grant was a community outreach programme called Science on Screen, and because of this, the Feats of Modest Valour documentary was born. It was commissioned by the Science Foundation Ireland Centre for Research in Medical Devices (CÚRAM) and the Galway UNESCO City of Film and Galway Film Centre.

Several projects were pitched to film makers to connect with the general public, and as a result of our pitch which revolved around the gene-environment interaction and increased susceptibility in Parkinson’s disease, ISHKA Films (Alice McDowell and Mia Mullarkey) production company decided to focus on our work. As part of the Horizon 2020 grant, the brain mattrain project is focussing on the development of a new biomedical device for Parkinson’s disease which will, for the first time, target the underlying cause of Parkinson’s disease rather than purely addressing the motor symptoms.

One of the most appealing aspects of the project was the platform for engaging with the general public. There is so much fascinating research being performed for a host of diseases all over Ireland but yet there sometimes seems to be a disconnect between that and the very people who the research will have the most impact on.

This was something we were very interested in when we hosted a conference in Galway in 2014. For the NECTAR (Network for European CNS Transplantation and Restoration) conference, which brings together a unique audience of clinicians and scientists from all over the world to disseminate their research and results of clinical trials. We wanted to do something different, to broaden the scope of the conference, so we integrated a patient-oriented focus into the programme.  The founder of Cure Parkinson’s UK, Tom Isaacs (1968-2017), who was diagnosed with the disease when he was only 27, attended the event and spoke passionately about trying to bridge the gap between clinicians, scientists and patients.  Being part of FOMV gave us the opportunity to do this, to merge science and real life.

It helped therefore that I had been spending quite a lot of time with Brian and with people from the Parkinson’s Association of Ireland.  It has several branches all over the country so I spent quite a lot of time talking with them, organising charity walks, hosting information days and securing funding for speech and language therapists for them. Considering the wealth of knowledge that you can acquire throughout the course of a PhD, it is really rewarding being able to give something back.

When I look back, easily the best part about FOMV was spending time with people with Parkinson’s disease. It is quite easy to forget the bigger picture, the reason why you set out to do research in the first place. This was an opportunity for me to interact with people who were suffering with Parkinson’s disease and talk with them and explain to them about our research. The platform for relaying scientific research to the general public is definitely an under-utilised one. For the majority of research, people do not know what is going on. When the tailor for the documentary was first shown to people, the most common response you heard back was: “I can’t believe this is happening on our backdoor,” or “That was so easy to follow and to understand,” or “Why don’t more scientists do this to explain their research to us?”

Our documentary was recently submitted to a film festival in New York called the Imagine Science Films (ISF) festival, in collaboration with the American Association for the Advancement of Science (AAAS). The select jury included Nobel prize-winning scientist Professor Martin Chalfe, and award-winning science columnist for the New York Times, Professor Carl Zimmer.

We were absolutely delighted when FOMV won The Scientist Award, which is awarded to a film that portrays, accurately and importantly inventively, the life of a scientist. The goal of this award is to encourage more scientists to create films that let people into their minds, into their labs and into their lifestyle. In addition to the top science award, FOMV was also awarded runner up People’s Choice Award. This award is presented to the documentary that receives the most audience votes during the festival.

Being part of Feats of Modest Valour was definitely one of the most humbling experiences I have ever had. I have met so many people who suffer with Parkinson’s disease and in the face of such a relentless disease, they have such incredible resolve to make the most of their lives. We tend to take so much for granted and forget to appreciate the little things. And while that sounds very clichéd, Milena, Brian and Tom are no longer in a position to do that. They live a completely clockwork existence based around the particular time when they take their medication. And even then, their days are more bad than good.

That’s why the title of the documentary ‘Feats of Modest Valour’ is based on a poem called ‘No signs of struggle,’ by an American poet named Robin Morgan, who was diagnosed with Parkinson’s disease;

“You can spot it in the provocation of a button, an arm poking at a sleeve, a balancing act at a night-time curb while negotiating the dark. Feats of such modest valour, who would suspect them to be exercises in an intimate, fierce discipline, a metaphysics of being relentlessly aware.”

 

Make sure to tune in to RTE One on Sunday 12th of November, when ‘Feats of Modest Valour’ is on at 10.35pm.

For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.

For current vacancies in our team, visit careers.randox.com

 


Randox responds to antibiotic resistance warning from NI Chief Medical Officer Dr. Michael McBride

Today, Northern Ireland’s Chief Medical Officer Dr. Michael McBride has stated that antibiotic resistance is now the greatest risk to human health and medicines worldwide. Dr. McBride said; “Currently 700,000 people die worldwide each year from drug resistant infections and this figure is forecasted to reach 10 million deaths by 2050, if the problem is ignored.”

It is rather alarming therefore that 70% of GPs admit that they prescribe antibiotics when they are unsure if they are treating a viral or bacterial infection. By prescribing antibiotics for viral infections, which can’t be combatted with antibiotics, patients are being exposed to antibiotics which are of no benefit.

John Lamont, Lead Scientist at Randox Laboratories, said that “Current diagnostic testing for respiratory infections takes at least 36 hours to confirm the nature of an infection, and they cannot name and categorise infections as bacterial or viral is the way our new respiratory test can.”

At Randox, our pioneering R&D teams have developed a revolutionary swab test for respiratory infections which indicates the cause of the infection and whether a patient needs antibiotics or not. This helps to limit the amount of patients who are prescribed antibiotics, reducing antibiotic resistance.

The Randox test, which can rapidly detect and identify the cause of 21 respiratory infections in just 5 hours, can also subsequently determine the appropriate antibiotic drug treatment for patients.

This test, if adopted by GP surgeries, could allow medical practitioners to make the correct treatment choice on the same day as examination and before patients have already begun a precautionary course of inefficient antibiotics.  It would also have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily prescribing drugs which are not needed.  This new rapid and accurate test will give the GP confidence in their diagnosis of respiratory infections and will allow for quicker treatment if necessary, which benefits patient outcomes.

The test is also available as a Randox Health Cough, Cold & Flu offering, and can be carried out by booking an appointment with Randox Health at our clinics in Crumlin, Holywood or London, or by arranging the mobile clinic to visit you at your home or place of work.

So what action can we take to limit the looming antibiotic resistance crisis?

  1. Ask your GP if tests will be performed to make sure you even need antibiotics and that the correct antibiotic is prescribed.
  2. Take the antibiotics as prescribed. Make sure you complete the prescribed course, even when you start feeling better. This makes sure that all bacteria from your current infection are eradicated, leaving none behind that could potentially develop resistance to your antibiotic.
  3. Only take antibiotics prescribed for you; do not share or use leftover antibiotics. Taking the wrong medication will delay correct treatment and allow bacteria to multiply, and potentially develop a resistance to the antibiotic you are using incorrectly.

Find out more about the Cough, Cold & Flu Respiratory test here.

Book an appointment with one of our clinics, or arrange the mobile clinic, by phoning 0800 2545 130 or by clicking here.

For further information please contact the Randox PR team by email: randoxpr@randox.com or phone 028 9442 2413


Welcome to the Evidence Series

Introduction

For over 30 years, we have been researching and manufacturing market-leading diagnostics products globally. With a mission statement of ‘dedicated to improving health worldwide’ the patient needs are a central focus of everything we do. It is this experience and commitment to improving healthcare that has allowed us to continually improve our product offering and make advancements globally to reach as many people as possible and provide greater diagnostic facilities.

From this experience and commitment to research, we believe we have developed a technology that has changed diagnostic testing forever.

Biochip Array Technology

In 2002, we invented a world first, which changed the landscape of diagnostic testing forever. Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.

Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.

An individual biochip has up to 49 Discrete Test Regions with each detecting a different biomarker. That means up to 44 tests can be carried out simultaneously, with the additional DTRs being reserved for visual quality control and visual reference; a feature unique to Biochip Array Technology.

The Evidence Series

Having developed this patented technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series. The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.

Have a read below of the brief overview of each analyser in the Evidence Series

Evidence Evolution

The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.

Evidence

As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.

Evidence Investigator

The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.

Evidence MultiSTAT

The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.

 

About the Randox Evidence Series

The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities. For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Clinical Laboratory Survey